$AMRX News

Will Amneal (AMRX) Beat Estimates Again in Its Next Earnings Report?

Amneal Pharmaceuticals (AMRX) Faces A Valuation Test Following Slowing Growth Concerns

JP Morgan Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $24

Amneal to Report Third Quarter 2026 Results on November 3, 2026

Amneal Pharmaceuticals (AMRX) Stock Gets Fair Value Bump After Analyst Backing For New Launches

Oppenheimer Initiates Coverage On Amneal Pharmaceuticals with Outperform Rating, Announces Price Target of $27

Amneal: Even My Bull Case Barely Justifies $20/Share

Why Is Amneal (AMRX) Stock Rocketing Higher Today

Amneal Announces FDA Approval and Launch of Lanreotide Injection

3 Reasons to Avoid AMRX and 1 Stock to Buy Instead

Barclays Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $20

Insider Unloading: KEVIN BUCHI Sells Options, Realizes $54K

Leerink Partners Initiates Coverage On Amneal Pharmaceuticals with Outperform Rating, Announces Price Target of $23

Does Amneal’s Post‑Earnings Shelf Registration Reshape the Bull Case for Amneal Pharmaceuticals (AMRX)?

Amneal Pharmaceuticals (AMRX) Bets Big On Biosimilars While Wall Street Retreats

Amneal Pharmaceuticals (AMRX) Stock Sees Modest Fair Value Lift On Launch Optimism

Amneal Pharmaceuticals Files Prospectus Related To The Offer And Sale Of Up To 28,942,098 Shares of Class A Common Stock By Selling Stockholders

Generic Pharmaceuticals Stocks Q2 Results: Benchmarking Amneal (NASDAQ:AMRX)

JP Morgan Reinstates Overweight on Amneal Pharmaceuticals, Announces $22 Price Target

Is Amneal Pharmaceuticals (AMRX) Fairly Valued After A 3.5x Return?